Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07024277CT.gov Study of ZG006 in Participants With Neuroendocrine Prostate Cancer | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| zg006 (this asset) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | P2 | CCC · 53 |
| Carboplatin | Phanes Therapeutics | P2 | B |
| Oxodotreotide | Novartis Pharmaceuticals | P2 | B |
| Tarlatamab | Inkeun Park | P2 | B |
| Alisertib | Weill Medical College of Cornell University | P2 | B |
| Olaparib | National Cancer Institute (NCI) | P2 | CCC |
| Sacituzumab Tirumotecan | Virginia Commonwealth University | P2 | CCC |
| Memantine Hydrochloride | Bin Xu | P2 | CCC |
| Tislelizumab | Translational Research in Oncology | P2 | CCC |
+26 more in the Prostate Neuroendocrine Neoplasm cohort
Other indications for zg006
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P3 | B · 60 |
| Neuroendocrine Carcinoma | — | P1/2 | CC · 45 |
| Neoplasm | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. zg006 in Prostate Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zg006-prostate-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →